A JNCCN study reported that broad-based genomic sequencing before treatment is associated with longer survival in patients with advanced non-small cell lung cancer. The analysis links upfront molecular profiling to improved outcomes, positioning sequencing as more than a diagnostic step. While the study is observational, the result adds weight to the clinical move toward comprehensive testing at diagnosis or prior to therapy selection, where actionable alterations can guide targeted treatment strategies. In advanced settings, selection effects and access differences can influence outcomes, but broad sequencing is still being increasingly treated as a patient-level decision tool. The finding supports continued investment in sequencing capacity and trial designs that test how early genomic information changes treatment trajectories.